Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 3728429, 3 pages
https://doi.org/10.1155/2017/3728429
Case Report

Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML

1Washington University School of Medicine, St. Louis, MO, USA
2Siteman Cancer Center, St. Louis, MO, USA

Correspondence should be addressed to Armin Ghobadi; ude.ltsuw@idabohgnimra

Received 8 November 2016; Accepted 2 February 2017; Published 20 February 2017

Academic Editor: Masayuki Nagasawa

Copyright © 2017 Bita Fakhri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Posttransplant Lymphoproliferative Disorder (PTLD) is one of the most common malignancies complicating solid organ transplantation. In contrast, PTLD accounts for a minority of secondary cancers following allogeneic hematopoietic cell transplantation (HCT). Here we report on a 61-year-old woman who received an ABO-mismatched, HLA-matched unrelated donor hematopoietic cell transplantation from a presumably healthy donor for a diagnosis of acute myeloid leukemia (AML). Eighteen months following her transplant, she developed a monoclonal gammopathy. Bone marrow studies revealed 10% plasma cells, but the patient lacked clinical defining features of multiple myeloma (MM); thus a diagnosis of smoldering multiple myeloma (SMM) was established. Cytogenetic and molecular studies of the bone marrow confirmed the plasma cells were donor-derived. The donor lacks a diagnosis of monoclonal gammopathy of undetermined significance, SMM, or MM.